.jpg?format=webp&width=780)
Aurobindo Pharma's subsidiary has secured final approval from the US FDA for its generic version of Plerixafor injection, used to prepare cancer patients for stem cell transplants. The approval allows the manufacture and marketing of the injection in strengths of 24 mg/1.2 mL (20 mg/mL). The product is indicated for patients with non-Hodgkin's lymphoma or multiple myeloma, to mobilize hematopoietic stem cells for transplantation.
Like
Save
Share